Collectively, these conclusions strongly suggest that selinexor can be a promising therapeutic agent for TNBC as only one agent and in combination with standard chemotherapy. 陶术生物 陶术生物 One of the sensitive DLBCL mobile strains, we selected SUDHL6 for creating a subcutaneous xenograft design in six-7 days-previous male NCG mice. and https://casse207ydi1.wikisona.com/user